Ney Carter Borges: The Optimal DAPT Duration in High Bleeding Risk PCI Patients
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn about a recent article by Andrea Zito et al, published in JAMA, adding:
”Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: Updated Evidence From a Systematic Review and Meta-analysis
This systematic review and meta-analysis evaluated the optimal duration of dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).
Fourteen randomized controlled trials involving 11,398 HBR patients (mean age 74.7 years; 39.1% women; 61.2% presenting with acute coronary syndrome) were included. The analysis compared abbreviated DAPT (1–3 months) with conventional DAPT (6–12 months), while excluding patients requiring chronic oral anticoagulation.
Abbreviated DAPT significantly reduced major or clinically relevant non-major bleeding by 29% (RR 0.71, 95% CI 0.55–0.92; P=0.009) and major bleeding by 24% (RR 0.76, 95% CI 0.59–0.99; P=0.04).
Importantly, these bleeding benefits were achieved without increasing ischemic complications, including major adverse cardiovascular events (MACE), myocardial infarction, stroke, cardiovascular death, or stent thrombosis.
Sensitivity analyses consistently confirmed the robustness of these findings.
Network meta-analysis demonstrated that both 1-month and 3-month DAPT regimens reduced bleeding compared with standard therapy.
However, although a single direct-comparison trial suggested a higher ischemic risk with 1-month versus 3-month DAPT, the overall network estimate was not statistically significant.
Collectively, the available evidence appears more reassuring for 3-month DAPT, which preserved ischemic protection while minimizing bleeding risk.
These findings reinforce contemporary individualized antithrombotic strategies, supporting shorter DAPT durations in carefully selected HBR patients after PCI.
For most HBR patients without an indication for oral anticoagulation, a 3-month DAPT strategy followed by single antiplatelet therapy provides the most favorable balance between bleeding reduction and ischemic safety, whereas routine 1-month DAPT warrants additional confirmation in future randomized trials.”
Title: Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis
Authors: Andrea Zito, Antonio Landi, Deepak L. Bhatt, Shao-Liang Chen, Giuseppe De Luca, Anna Franzone, Hyeon-Cheol Gwon, Jeehoon Kang, Joo-Yong Hahn, Sung-Jin Hong, Yangsoo Jang, Byeong-Keuk Kim, Hyo-Soo Kim, Takeshi Kimura, Roxana Mehran, Kyoung-Woo Park, Philippe Gabriel Steg, Gregg W. Stone, Pascal Vranckx, Stephan Windecker, Marco Valgimigli
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery